aridol- in discussions with distributor in europe. h2 complete usa aridol study first half of 05 cystic fibrosis study results available .and they wouldnt have the manufactoring scale up unless they thoguht they were on a winner.
also note thatthey expect phase 3 registration of bronchiectasis by end of 2005.
note 71% of stock is held by insto's founders and VC,s plus mgment.
so 29% puntable thats if they will sell
PXS Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
